Abstract:Antimicrobial peptides are proposed to activate the cGAS‐STING pathway by promoting mitochondrial DNA leakage, providing a new insight for the design of novel STING agonists. Furthermore, a multi‐stimuli activatable peptide nanodrug is designed for site‐specific delivery of different peptides, simultaneously activating the cGAS‐STING pathway and blocking PD‐1/PD‐L1 pathway, ultimately initiating robust and durable T cell anti‐tumor immunity. As an essential intracellular immune activation pathway, the cGAS‐STING pathway has attracted broad attention in cancer treatment. However, low bioavailability, nonspecificity, and adverse effects of small molecule STING agonists severely limit their therapeutic efficacy and in vivo application. In this study, a peptide‐based STING agonist is first proposed, and KLA is screened out to activate the cGAS‐STING pathway by promoting mitochondrial DNA (mtDNA) leakage. To precisely activate the cGAS‐STING pathway and block the PD‐1/PD‐L1 pathway, a multi‐stimuli activatable peptide nanodrug (MAPN) is developed for the effective delivery of KLA and PD‐L1 antagonist peptide (CVR). With rational design, MAPN achieved the site‐specific release of KLA and CVR in response to multiple endogenous stimuli, simultaneously activating the cGAS‐STING pathway and blocking PD‐1/PD‐L1 pathway, ultimately initiating robust and durable T cell anti‐tumor immunity with a tumor growth inhibition rate of 78% and extending the median survival time of B16F10 tumor‐bearing mice to 40 days. Overall, antimicrobial peptides, which can promote mtDNA leakage through damaging mitochondrial membranes, may be potential alternatives for small molecule STING agonists and giving a new insight for the design of novel STING agonists. Furthermore, MAPN presents a universal delivery platform for the effective synergy of multiple peptides.

Fluorinated cGAMP analogs, which act as STING agonists and are not cleavable by poxins: Structural basis of their function

Novel Poxin Stable cGAMP‐Derivatives Are Remarkable STING Agonists

Design, Synthesis and Biological Evaluation of (2′,5′ and 3′5′-Linked) cGAMP Analogs that Activate Stimulator of Interferon Genes (STING)

Design and syntheses of a bimolecular STING agonist based on the covalent STING antagonist

Arabinose- and xylose-modified analogs of 2',3'-cGAMP act as STING agonists

Structure−Activity Relationship Study of Benzothiophene Oxobutanoic Acid Analogues Leading to Novel Stimulator of Interferon Gene (STING) Agonists

Distinct Dynamical and Conformational Features of Human STING in Response to 2'3'-cGAMP and c-di-GMP.

Discovery of Novel STING Inhibitors Based on the Structure of the Mouse STING Agonist DMXAA

2',4'‐LNA‐Functionalized 5′‐S‐phosphorothioester CDNs as STING agonist

A non-nucleotide agonist that binds covalently to cysteine residues of STING

Discovery of Novel Thieno[2,3-d]imidazole Derivatives As Agonists of Human STING for Antitumor Immunotherapy Using Systemic Administration.

A Novel Transcript Isoform of STING That Sequesters Cgamp and Dominantly Inhibits Innate Nucleic Acid Sensing

Roles of Water Molecules in STING Activation: A Computational Perspective

Orally Bioavailable STING Antagonist Synthesized via Multi-component Povarov-Doebner Type Reaction

Prolonged activation of innate immune pathways by a polyvalent STING agonist

Precisely Activating cGAS‐STING Pathway with a Novel Peptide‐Based Nanoagonist to Potentiate Immune Checkpoint Blockade Cancer Immunotherapy

Activation of human STING by a molecular glue-like compound

Exploration of the Binding Mechanism of Cyclic Dinucleotide Analogs to Stimulating Factor Proteins and the Implications for Subsequent Analog Drug Design

Development of an orally bioavailable covalent STING inhibitor

Agonists and Inhibitors of the Cgas-Sting Pathway

Targeting STING oligomerization with small-molecule inhibitors